Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling

摘要: Lung cancer is the most deadly neoplasm with highest incidence in both genders, non-small cell lung (NSCLC) being frequent subtype. Somatic mutations within tyrosine kinase domain of epidermal growth factor receptor (EGFR) gene are key drivers NSCLC progression, EGFR inhibitors particularly beneficial for patients carrying so-called “EGFR-sensitizing mutations”. However, eventually acquire resistance to these inhibitors, and a better knowledge other driven targetable proteins will allow design increasingly accurate drugs against patients’ specific molecular aberrations. Raf inhibitory protein (RKIP) an important modulator relevant intracellular signaling pathways, including those controlled by EGFR, such as MAPK. It has been reported that it metastasis suppressor activity prognostic role several solid tumors, cancer. In present review, potential use RKIP clinic biomarker predictor therapy response addressed.